



File No.: 6013-106US

Québec, Canada

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: RICHARD BELANGER

Serial No.: 10/519,844

Filing Date: AUGUST 29, 2005

Art Unit: 1614

Title: ANTIMICROBIAL MOLECULE

FIRST INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97

NO FEE

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith on a PTO-1449 form is a listing of the documents known to applicant in order to comply with applicant's duty of disclosure pursuant to 37 C.F.R. § 1.56.

The submission of any document which is not a statutory bar is not intended as an admission that such document constitutes prior art against the claims of the present application. Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a <u>prima facie</u> prior art reference against the claims of the present application.

Statement of Relevancy

The listed document is being submitted either in compliance with 37 C.F.R. §1.97(b), within three (3) months of the filing date of a national application or of the date of entry of the national stage in an international application, or before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under §1.114; or pursuant to 37 C.F.R. §1.97(e)(1), within three (3) months from the date of an office action or of a search report issued in a foreign counterpart application citing each of the documents contained in the present statement; or pursuant to 37 C.F.R. §1.97(e)(2), within three (3) months from the first knowledge of each submitted document by any individual designated in C.F.R. §1.56(c), when each such document was not cited in a communication from a foreign patent office in a counterpart foreign application.

In the case of submission under 37 C.F.R. §1.97(e)(1) and (2), the undersigned Attorney/Agent of Record hereby certifies that the enclosed list of references is hereby submitted within three months (1) from the issuance of the foreign action or search report, or (2) from said first knowledge, respectively.

The Examiner is kindly requested to consider these references during the examination of the above-identified application, making the references of record, and to return an initialed copy of the PTO-1449 Form to the below-signed agent.

January 18, 2006

Date

Respectfully,

Agent of the Applicant

Michel Bélanger, Reg. No. 38,015

OGILVX RENAULT LLP

Customer Number:

PTO/SB/08A/B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required respond to a collection of information unless it displays a valid OMB control number.

Complete if Known Substitute for form 1449A and B/PTO Application Number 10/519844 **INFORMATION DISCLOSURE** Filing Date 07/29/2005 First Named Inventor Richard Belanger STATEMENT BY APPLICANT Art Unit (use as many sheets as necessary) Examiner Name Sheet 1 of 2 Attorney Docket Number 60013-106US MG/pd

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		US 6,350,748	02/26/2002	Takeyama et al.	
			1		
			 		
			-		
			-		
			_		
			1		
			1		
			 		

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant Of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear			
		Country Code3 - Number4 - Kind Code5 (if known)	MM-DD-YYYY			Τ ⁶		
		JP-A-2000169495	06/20/2000	Ikedou Kouji				
		WO 97/00255	01/03/1997	Raymond Lovey et al.				
	<u> </u>					+		
	1					+		
	 					+		
						-		
·						+		
	<u> </u>					+		
	 							

Approved for use through 10/31/2002. OMB 0651-0031

Approved for use through 10/31/2002. OMB 0651-0031

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are definited to responded a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A and B/PTO		THE	Complete if Known		
		TO THAPPEN	Application Number	10/519844	
INFORMATION DISCLOSURE			CLOSURE	Filing Date	07/29/2005
STATEMENT BY APPLICANT				First Named Inventor	Richard Belanger
				Art Unit	1614
(use as many sheets as necessary)			ecessary)	Examiner Name	
Sheet	2	of	2	Attorney Docket Number	6013-118US MG/pd

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examin er Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Y.L. CHENG ET AL. « Establishment of a gene transfer system for Pseudozyma flocculosa, an antagonistic fungus of powdery mildew fungi" Mol Gent Genomics, 2001, 266:96-102	
		LANG S ET AL. "Antimicrobial Effects of Biosurfactants » Fett Wissenschaft Technologie – Fat Science Technology, Conradin Industrieverlag. LEinfelden Echterdingen, DE, vol. 91, no. 9, 1989, pages 363-366	

Examiner Signature	Date Considered	
Olgitaturo	Gonolagica	

^{*}EXAMINER; Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.